Andrew Baum
Stock Analyst at Citigroup
(2.82)
# 1,784
Out of 4,876 analysts
63
Total ratings
69.77%
Success rate
12.55%
Average return
Main Sectors:
Stocks Rated by Andrew Baum
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MRK Merck & Co. | Downgrades: Neutral | $115 → $84 | $79.15 | +6.13% | 14 | May 14, 2025 | |
| PFE Pfizer | Maintains: Neutral | $30 → $29 | $24.36 | +19.07% | 10 | Jan 28, 2025 | |
| BMY Bristol-Myers Squibb Company | Maintains: Neutral | $60 → $65 | $46.69 | +39.22% | 11 | Jan 28, 2025 | |
| RPRX Royalty Pharma | Maintains: Buy | $60 → $40 | $35.32 | +13.25% | 2 | Oct 25, 2024 | |
| ABBV AbbVie | Maintains: Buy | $170 → $215 | $186.63 | +15.20% | 10 | Oct 25, 2024 | |
| LLY Eli Lilly and Company | Maintains: Buy | $675 → $895 | $797.56 | +12.22% | 11 | Apr 2, 2024 | |
| ALVO Alvotech | Upgrades: Neutral | $5 → $10 | $9.42 | +6.16% | 3 | Oct 20, 2023 | |
| GSK GSK plc | Downgrades: Neutral | n/a | $38.70 | - | 2 | Jul 5, 2017 |
Merck & Co.
May 14, 2025
Downgrades: Neutral
Price Target: $115 → $84
Current: $79.15
Upside: +6.13%
Pfizer
Jan 28, 2025
Maintains: Neutral
Price Target: $30 → $29
Current: $24.36
Upside: +19.07%
Bristol-Myers Squibb Company
Jan 28, 2025
Maintains: Neutral
Price Target: $60 → $65
Current: $46.69
Upside: +39.22%
Royalty Pharma
Oct 25, 2024
Maintains: Buy
Price Target: $60 → $40
Current: $35.32
Upside: +13.25%
AbbVie
Oct 25, 2024
Maintains: Buy
Price Target: $170 → $215
Current: $186.63
Upside: +15.20%
Eli Lilly and Company
Apr 2, 2024
Maintains: Buy
Price Target: $675 → $895
Current: $797.56
Upside: +12.22%
Alvotech
Oct 20, 2023
Upgrades: Neutral
Price Target: $5 → $10
Current: $9.42
Upside: +6.16%
GSK plc
Jul 5, 2017
Downgrades: Neutral
Price Target: n/a
Current: $38.70
Upside: -